Ardelyx, Inc. (NASDAQ:ARDX) reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report.
The Details: Ardelyx reported quarterly sales of $98.24 million, which beat the analyst consensus estimate of $86.64 million.
The company reported IBSRELA generated $40.6 million in net product sales revenue and the company expects full-year 2024 IBSRELA net sales revenue to be between $145 million and $150 million.
XPHOZAH generates $51.5 million in net product sales revenue and Ardelyx ended the quarter with approximately $190 million in cash, cash equivalents and investments.
Read Next: Reddit ‘Remains A Favorite’ For Wall Street After ‘Emphatic Beat And Raise’ In Q3
“The continued strong performance of Ardelyx reported during the third quarter demonstrates our ability to execute and deliver on our goals, to focus on serving the patient and to build towards the future,” said Mike Raab, president and CEO of Ardelyx.
ARDX Price Action: According to Benzinga Pro, Ardelyx shares are up 3.07% after-hours at $6.05 at the time of publication Thursday.
Read Also:
Photo: HeungSoon from Pixabay
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。